Kusumoto S, Tachibana T. Central nervous system management remains an evidence gap in first-line tagraxofusp therapy for blastic plasmacytoid dendritic cell neoplasm. Comment on: “First-line tagraxofusp leads to durable responses and prolonged survival in adults with blastic plasmacytoid dendritic cell neoplasm regardless of fitness level”. Haematologica; https://doi.org/10.3324/haematol.2026.301865 [Early view].